---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-208095"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:31:56.782933+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cabaletta Bio Q2 2023: cash $176.3M; IND cleared for CABA-201 in myositis

## Summary
- Cash, equivalents & investments of $176.3M as of June 30, 2023, extending runway into Q4 2025.
- Net proceeds of ~$93.8M from May 2023 public offering of 8,337,500 shares at $12.00/share.
- R&D expenses $11.8M (Q2 2023) vs $9.5M (Q2 2022); G&A $4.1M vs $3.5M.
- FDA cleared second IND for CABA-201 in myositis; Fast Track designation granted for SLE/LN.
- Anticipates initial 3-month clinical data for CABA-201 by first half of 2024.

## SEC filing metadata
- accession: 0001193125-23-208095
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000119312523208095/0001193125-23-208095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000119312523208095/d538476d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-208095
- JSON: https://secwatch.observer/filing/0001193125-23-208095.json
- Plain text: https://secwatch.observer/filing/0001193125-23-208095.txt

## Key facts
- Earnings Releases
  Cabaletta Bio, Inc. reported financial results for second quarter ended June 30, 2023.
  - Period: second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 10, 2023, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759138/000119312523208095/0001193125-23-208095-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.